Benefiting from the resilience of the oncology franchisee, sales momentum accelerated in Q4 and the FY20 targets were exceeded. Assuming the phased launch of Somatuline’s generic in Europe, management seems cautious with its FY21 outlook, but considering that the generic is going through a slow and staggered launch, upgrades can’t be ruled out. Label extension of Cabometyx should also lend support. Given the firepower of €1.3bn, management’s focus is to replenish the pipeline through external in ....
15 Feb 2021
Strong finish to the year led by oncology
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong finish to the year led by oncology
Benefiting from the resilience of the oncology franchisee, sales momentum accelerated in Q4 and the FY20 targets were exceeded. Assuming the phased launch of Somatuline’s generic in Europe, management seems cautious with its FY21 outlook, but considering that the generic is going through a slow and staggered launch, upgrades can’t be ruled out. Label extension of Cabometyx should also lend support. Given the firepower of €1.3bn, management’s focus is to replenish the pipeline through external in ....